Published in Expert Rev Clin Immunol on September 01, 2009
Reduced PARP1 as a Serum Biomarker for Graft Rejection in Kidney Transplantation. J Proteomics Bioinform (2016) 0.75
Non-invasive imaging of allogeneic transplanted skin graft by 131I-anti-TLR5 mAb. J Cell Mol Med (2014) 0.75
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Regulatory T cells in transplantation tolerance. Nat Rev Immunol (2003) 6.42
Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med (2005) 5.02
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant (2006) 3.78
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med (2001) 3.16
Induction of antibody-forming cell clones in microcultures. Eur J Immunol (1972) 2.98
Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest (2008) 2.73
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
Human allograft acceptance is associated with immune regulation. J Clin Invest (2000) 1.94
Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol (2002) 1.81
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol (2005) 1.72
Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol (2004) 1.67
Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol (2008) 1.62
Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation (2007) 1.50
Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol (2004) 1.49
Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int (2004) 1.48
Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant (2003) 1.47
The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant (2008) 1.33
Safety and adequacy of renal transplant protocol biopsies. Am J Transplant (2005) 1.30
How can we measure immunologic tolerance in humans? J Am Soc Nephrol (2006) 1.29
Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation (2009) 1.26
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation (2007) 1.18
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation (2002) 1.14
Immunologic monitoring. Immunol Rev (2003) 1.13
Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation (1998) 1.13
Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation (2008) 1.11
Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med (2007) 1.10
Sensitization after kidney transplantation. Clin J Am Soc Nephrol (2006) 1.09
Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol (2003) 1.09
Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant (2008) 1.07
Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant (2007) 1.05
Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol (2008) 1.04
Challenges to achieving clinical transplantation tolerance. J Clin Invest (2001) 1.03
Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation (2004) 1.02
The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med (2002) 1.01
Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant (2005) 1.00
Generation and function of antigen-specific suppressor and regulatory T cells. Transpl Immunol (2003) 0.98
Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation (2003) 0.96
Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol (1999) 0.96
Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol (2005) 0.95
Preceeding the rejection: in search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol (2007) 0.95
Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant Proc (2007) 0.93
Beyond histology: novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol (2006) 0.93
The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation. Transplant Proc (2007) 0.92
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Homeostatic T cell proliferation as a barrier to T cell tolerance. Philos Trans R Soc Lond B Biol Sci (2005) 0.91
Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation (2004) 0.90
Tailoring of immunosuppression in renal and liver allograft recipients displaying donor specific T-suppressor cells. Hum Immunol (2002) 0.89
Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol (2005) 0.87
Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant (2005) 0.86
Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant (2006) 0.86
Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol (2005) 0.85
Increased lung allograft failure in patients with HLA-specific antibody. Clin Transpl (2007) 0.83
Microarrays: monitoring for transplant tolerance and mechanistic insights. Clin Lab Med (2008) 0.83
Immune monitoring in organ transplantation using neopterin. Curr Drug Metab (2002) 0.82
Accumulation of T cells with potent regulatory properties and restricted Vbeta7-TCR rearrangements in tolerated allografts. Transplantation (2005) 0.82
Tapering immunosuppression in recipients of living donor kidney transplants. Nephrol Dial Transplant (2004) 0.82
Clinical significance of in vitro donor-specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR. Transpl Int (1994) 0.79
Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum Immunol (1999) 0.79
Control of anti-donor antibody production post-transplantation: conventional and novel immunosuppressive therapies. Contrib Nephrol (2008) 0.79
T helper frequencies in peripheral blood reflect donor-directed reactivity in the graft after clinical heart transplantation. Clin Exp Immunol (1999) 0.78
Improved long-term graft function in kidney transplant recipients with donor antigen-specific hyporeactivity. Pediatr Transplant (2007) 0.78
Limiting dilution analysis: quantification of IL-2 producing allospecific lymphocytes after renal and cardiac transplantation. Transpl Immunol (1994) 0.78
Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation (2007) 0.77
Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation (2006) 0.77
Immunological monitoring as a guide to the management of transplant recipients. Surg Clin North Am (1979) 0.76
Molecular heterogeneity in acute renal allograft rejection and DNA microarrays. N Engl J Med (2003) 0.76
Microarrays: interrogating the transplant transcriptosome. Clin Transpl (2004) 0.76
Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation? Transplant Proc (2008) 0.76
Tapering immunosuppressive therapy significantly improves in vivo cutaneous delayed type hypersensitivity responses. Transpl Immunol (2008) 0.76
Lymphocyte depletion for kidney transplantation: back to the past? Nat Clin Pract Nephrol (2008) 0.76
Evidence of donor-specific cellular suppressor activity in donor-specific cell-mediated lympholysis unresponsiveness in renal transplant patients. Transplantation (1987) 0.76
In vivo mechanisms of alloreactivity. II. Allospecificity of cytotoxic T lymphocytes in sponge matrix allografts as determined by limiting dilution analysis. Transplantation (1986) 0.76
A practical approach to immune monitoring in kidney transplantation. Minerva Urol Nefrol (2007) 0.75
Changes in donor-specific cell-mediated lympholysis (CML) response associated with success of early steroid withdrawal in DST-azathioprine-treated renal transplant recipients. Transplant Proc (1989) 0.75
Insights into subclinical rejection. Transplant Proc (2004) 0.75
Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant (2005) 2.70
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48
Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation (2014) 2.26
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet (2002) 1.76
Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation (2011) 1.51
Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation (2005) 1.40
Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant (2005) 1.25
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation (2002) 1.14
Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol (2008) 1.11
Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest (2006) 1.08
BK virus and SV40 co-infection in polyomavirus nephropathy. Transplantation (2002) 1.02
First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future. Pediatr Nephrol (2005) 0.94
The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. Transpl Immunol (2004) 0.92
Elevated expression levels of ANXA11, integrins β3 and α3, and TNF-α contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin Appl (2011) 0.89
Chemokines and their receptors in human renal allotransplantation. Transplantation (2011) 0.87
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87
Obesity following kidney transplantation and steroid avoidance immunosuppression. Clin Transplant (2008) 0.86
A reproducible mouse model of chronic allograft nephropathy with vasculopathy. Kidney Int (2012) 0.84
Successful renal transplantation in a patient with congenital generalized lipodystrophy: a case report. Am J Transplant (2004) 0.83
Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. Am J Transplant (2003) 0.83
Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325. J Am Soc Nephrol (2005) 0.81
Idiopathic intracranial hypertension following kidney transplantation: a case report and review of the literature. Pediatr Transplant (2005) 0.80
Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int (2005) 0.80
Surgical transplant physical examination: correlation of renal resistance index and biopsy-proven chronic allograft nephropathy. J Am Coll Surg (2005) 0.79
Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation (2011) 0.79
A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation (2016) 0.79
Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling. Transpl Int (2014) 0.79
Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy. J Mol Diagn (2010) 0.78
Solid organ transplantation at the National Institutes of Health: development of a research-based transplantation practice. Clin Transpl (2005) 0.78
Immunodiagnostics: evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. J Immunotoxicol (2007) 0.77
Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Transplantation (2012) 0.77
Lymphocyte depletion for kidney transplantation: back to the past? Nat Clin Pract Nephrol (2008) 0.76
C3 polymorphisms and outcomes of renal allografts. N Engl J Med (2009) 0.76
Leflunomide therapy in kidney transplantation: ready for prime time? Clin J Am Soc Nephrol (2008) 0.75
Low-density array PCR analysis of reperfusion biopsies: an adjunct to histological analysis. Nephrol Dial Transplant (2010) 0.75
A case of late kidney allograft failure: a clinical pathological conference from American Society of Nephrology Kidney Week 2011. Clin J Am Soc Nephrol (2012) 0.75
Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events. Clin Transplant (2010) 0.75
Effect of a Mobile Web App on Kidney Transplant Candidates' Knowledge About Increased Risk Donor Kidneys: A Randomized Controlled Trial. Transplantation (2016) 0.75
Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: results from a multicenter study. Transplantation (2010) 0.75
Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma. Transpl Int (2013) 0.75
Islet transplantation: need for a time-out? Nat Clin Pract Nephrol (2008) 0.75
The clinical application of monoclonal antibody therapies in renal transplantation. Expert Opin Emerg Drugs (2004) 0.75
Delayed autotransplantation of a solitary kidney facilitated by pump perfusion preservation. Surgery (2003) 0.75
Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors. Ann Surg (2017) 0.75
Diagnostic tools for monitoring kidney transplant recipients. Semin Nephrol (2007) 0.75
Care of the kidney transplant recipient. Clin J Am Soc Nephrol (2008) 0.75